Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05232240
Other study ID # BPV-NhICVD
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 14, 2022
Est. completion date February 2028

Study information

Verified date February 2022
Source Xuanwu Hospital, Beijing
Contact Xin Ma, MD, PhD
Phone 13501390691
Email maxin118@hotmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is a single-center prospective cohort of patients with ischemic cerebrovascular disease (ICVD) who have not met the diagnostic criteria for hypertension. Ambulatory 24-hour blood pressure monitoring (ABPM) will be performed at baseline and one year after the enrollment. The primary purpose of the study is to delineate the relationship of blood pressure variability (BPV) with the risk of composite vascular events in non-hypertensive patients with ICVD. The factors related to BPV, as well as the potential modulators of the associations between BPV and vascular risk, will be further explored among these patients.


Description:

Hypertension is one of the most important risk factors of ischemic cerebrovascular disease (ICVD), while various blood pressure variability (BPV) indices are immerging as novel prognostic indicators independent of the blood pressure level. However, the BPV profiles without hypertension have not been specifically observed. Considering the great importance of blood pressure management in ICVD, more research is needed to clarify whether and how BPV will increase the vascular risk in non-hypertensive patients with ICVD. This prospective cohort study will be helpful to invoke an early management of blood pressure in patients with ICVD before the clinical establishment of hypertension. All eligible non-hypertensive patients hospitalized for ICVD will be consecutively enrolled in this cohort. Blood pressure measurements are obtained with ambulatory 24-hour blood pressure monitoring (ABPM) every 20 minutes during day-time (6:00-22:00) and every 30 minutes during night-time (22:00-6:00) at baseline and one year after the enrollment. The clinical, imaging and laboratory information will be collected at baseline. During an estimated 3-year follow-up, the vessel-related diagnostic or monitoring procedures, treatment, functional status and new vascular events will be recorded by web-based patients' self-reports and investigators' regular telephone visits.


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date February 2028
Est. primary completion date February 2027
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Diagnosed as ischemic stroke or transient ischemic attack (TIA), with confirmation of computed tomography or magnetic resonance imaging. 2. Less than 90 days after onset of ischemic stroke or TIA symptoms. 3. The blood pressure measured 5~90 days after the ICVD onset without any anti-hypertension treatment is less than 140/90 mmHg (an average of =2 readings obtained on = 2 occasions after emptying bladder, relaxing for more than 5 min, and avoiding caffeine, exercise, or smoking for at least 30 min before measurement). 4. Consent to participate in the study. Exclusion Criteria: 1. A definite diagnosis of hypertension. 2. Under anti-hypertension treatment. 3. Worsening neurological conditions. 4. With a National Institute of Health Stroke Scale score more than 5 points. 5. Intracranial hemorrhage. 6. Autonomic failure. 7. With malignant tumors or poor organ functions or hematologic diseases, whose estimated life expectancy is less than 3 years. 8. With contraindications to ambulatory 24-hour blood pressure monitoring or fail to finish the examination at baseline. 9. Mental disease. 10. Pregnant.

Study Design


Intervention

Diagnostic Test:
blood pressure variability measured by ambulatory 24-hour blood pressure monitoring
The ambulatory 24-hour blood pressure monitoring will be performed at baseline and one year after the enrollment. Various blood pressure variability characteristics will be obtained from these examinations.

Locations

Country Name City State
China Xuanwu Hospital, Capital Medical University Beijing Beijing

Sponsors (1)

Lead Sponsor Collaborator
Xuanwu Hospital, Beijing

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary 3-year risk of Major Adverse Cardiovascular Event the time of first documented cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death), ischemic stroke, myocardial infarction or unstable angina 3 years
Secondary 90-day Functional Outcome percentage of patients with modified Rankin Scale (mRS) scores (minimum 0 and maximum 5) 3 to 5, who are considered to be disabled 90 days
Secondary 1-year rate of Major Adverse Cardiovascular Event the rate of cardiovascular mortality (any mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, and unobserved sudden death), ischemic stroke, myocardial infarction and unstable angina 1 year
Secondary 1-year rate of Ischemic Stroke the rate of fatal and nonfatal ischemic stroke 1 year
Secondary 1-year rate of Acute Coronary Syndrome the rate of first documented fatal and nonfatal myocardial infarction and unstable angina 1 year
Secondary 1-year rate of Cardiovascular Mortality the rate of mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, and unobserved sudden death 1 year
Secondary 3-year risk of Ischemic Stroke the time of first documented fatal or nonfatal ischemic stroke 3 years
Secondary 3-year risk of Acute Coronary Syndrome the time of first documented fatal or nonfatal myocardial infarction or unstable angina 3 years
Secondary 3-year risk of Cardiovascular Mortality the time of mortality due to ischemic stroke, myocardial infarction, other cardiac diseases, or unobserved sudden death 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT03589053 - Limb Remote Ischemic Conditioning and Cerebrovascular Reserve Phase 2
Enrolling by invitation NCT01925872 - Optimal Regimen in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance N/A
Not yet recruiting NCT03153878 - The Prospective Cohort Study on the Benefit-risk of Antithrombotic or Anticoagulant Therapy in Patients With Unruptured Intracranial Aneurysms Associated With Ischemic Heart Disease or Ischemic Cerebrovascular Disease N/A
Completed NCT02966418 - Hypoxic Preconditioning on Patients N/A
Not yet recruiting NCT06001073 - Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics
Recruiting NCT03794843 - Bioavailability Comparison Study of Two Types of Nimodipine Injections in Healthy Volunteers Early Phase 1
Not yet recruiting NCT05716646 - In the Real World Study, the Efficacy and Adverse Reactions of Ticagrelor on Ischemic Cerebrovascular Disease
Recruiting NCT03256513 - The Safety and Efficacy of Peri-procedure Blood Pressure Management of Revascularization N/A